Welcome to ATTACK
Analysis of the T cell’s Tactical Arsenal for Cancer Killing
Within the framework of this ERC Synergy Grant, an international team is researching the latest approaches in the fight against cancer cells. The focus is on so-called supramolecular attack particles (SMAPs), which are used by the body’s own defense cells (T cells) against tumor cells.
New biotechnology for more efficient cancer treatments
The research consortium aims at a more precise understanding of the mechanisms of action by which cytotoxic T cells act against tumor cells and to develop a new biotechnology for more efficient and more targeted cancer treatments.
For this, the consortium will analyze the so-called supramolecular attack particles (SMAPs), which are part of the T cells’ arsenal in the fight against tumor cells. The participating scientists in Homburg will analyze the exact release of SMAPs by the T-cells, scientists in Sienna will investigate the production of SMAPs, while the British scientists in Oxford will investigate the mode of action of the particles. And finally, the French research group in Toulouse will analyze how the tumor cells react to the attack by SMAPs. The consortium envisions that SMAPs will be freeze-dried and shipped around the world, solving problems related to current immunotherapies, leading to global health impact.
“This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 951329)”.